Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing

SAN CARLOS, Calif.--(BUSINESS WIRE)-- #DNAinnovation--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, includin